ArticleBMC cancer2026
Identification and validation of hub genes involved in papillary thyroid carcinoma progression.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrated transcriptomics approach identifies the upregulated SLC7A5, and associated pathways across different thyroid cancer cell types.Frontiers in genetics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Papillary Thyroid Cancer (PTC) is one of the most prevalent endocrine malignancies, and its incidence rate has almost tripled over the past three decades. The current study aimed to identify gene alterations and biomarkers contributing to PTC progression. Based on PTC transcriptome sequencing data, differential gene expression analysis is used to systematically categorize hub genes associated with PTC progression. A total of 1550 overlapping differentially expressed genes (DEGs) were identified in PTC compared to normal thyroid tissues, including 1149 upregulated and 401 downregulated genes. In addition, 3192 DEGs were detected in PTC relative to their normal adjacent tissues (NATs), comprising 1431 upregulated and 1761 downregulated genes. KEGG pathway analysis revealed pathways associated with cancer, proteoglycans in cancer, parathyroid hormone synthesis, and chemical carcinogenesis receptor activity. Protein-protein interaction (PPI) network analysis identified FN1, SDC1, and MAPK1 as highly ranked hub genes among the upregulated genes involved in several cancer pathways, including the PID Syndecan-1 pathway, Proteoglycans in cancer, and the CCL18 signaling pathway. The gene expression validation through Reverse Transcription-quantitative Polymerase Chain Reaction (RT-qPCR) further validated the significance of the above findings, demonstrating substantial upregulation of FN1 (7.4-fold increase), SDC1 (5.2-fold increase), and MAPK1 (5.8-fold increase) in papillary thyroid tissues relative to their adjacent normal tissues. Western blot analysis further validated the upregulation of FN1 at the protein level. These findings highlight a strong association between the identified hub genes (FN1, SDC1, and MAPK1) and papillary thyroid cancer, supporting their potential as diagnostic biomarkers and therapeutic targets. Further validation through in vivo experiments and functional assays will be essential to confirm their roles in PTC pathogenesis and to elucidate their clinical implications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.